Study of efficacy and tolerability for BAF312 compared to placebo in patients with polymyositis

Registry ID

EUCTR2012-002859-42

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2013-01-25

Completion date

2016-08-04

Last update

2026-08-16

Conditions

• Polymyositis

Summary

To assess the clinical effect of 2 mg BAF312 once daily in patients with PM over 12 weeks using both manual muscle testing (MMT-8) and serum creatine kinase (CK) as a combined endpoint

Locations

• , , Belgium
• , , Czechia
• , , Hungary
• , , Poland

Related clinical trials

• Adult and Juvenile Myositis
• Tübingen registry for autologous stem cell transplantation for severe autoimmune diseases
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
• Environmental Risk Factors for the Anti-synthetase Syndrome
• A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
• Rheumatology Patient Registry and Biorepository

View on source registry